TP63 Gene Complete Identifier and Functional Mapping Reference
Provide a comprehensive cross-database identifier and functional mapping reference for human TP63 — a definitive lookup resource covering: ### Section 1: Gene identifiers For human gene TP63, list ALL gene-level database identifiers. Required: - HGNC ID and approved symbol - Ensembl gene ID (ENSG...) - NCBI Entrez Gene ID - OMIM gene/locus ID - Genomic location: chromosome, start position, end position, strand (GRCh38) ### Section 2: Transcript identifiers For human gene TP63, list ALL transcript-level identifiers. Required: - Ensembl transcripts: ALL ENST IDs with biotype. Total count. - RefSeq transcripts: ALL NM_ mRNA accessions. Mark which is MANE Select. - CCDS IDs. - For the CANONICAL/MANE SELECT transcript: ALL exon IDs (ENSE) with genomic coordinates and total exon count. ### Section 3: Protein identifiers For human gene TP63 protein product(s), list ALL protein-level identifiers. Required: - UniProt accessions: ALL entries (reviewed and unreviewed). Mark the canonical reviewed entry. - RefSeq protein: ALL NP_ accessions. - Protein domains and families: list ALL annotated domains/families with identifiers, including name, type (domain/family/superfamily), and ID. - Antibody availability: known antibody resources for the protein. ### Section 4: Structure For human gene TP63 protein, list ALL structural data. Required: - Experimental structures: ALL PDB IDs. For each: experimental method (X-ray/NMR/Cryo-EM) and resolution. Total count. - Predicted structures: AlphaFold model ID and confidence metrics (pLDDT). ### Section 5: Cross-species orthologs For human gene TP63, list orthologous genes in key model organisms. Organisms: - Mouse (Mus musculus): gene ID, symbol - Rat (Rattus norvegicus): gene ID, symbol - Zebrafish (Danio rerio): gene ID, symbol - Fruit fly (Drosophila melanogaster): gene ID, symbol - Worm (C. elegans): gene ID, symbol - Yeast (S. cerevisiae): gene ID, symbol ### Section 6: Clinical variants & AI predictions For human gene TP63, summarize clinical variants and AI predictions. Clinical variant annotations (ClinVar): - Total variant count (approximate is fine) - Breakdown by classification: Pathogenic, Likely Pathogenic, VUS, Likely Benign, Benign - TOP 30 pathogenic/likely pathogenic variants with: variant ID, HGVS notation, associated condition AI-based variant effect predictions: - Splice effect predictions: total count + TOP 30 with delta scores if known - Missense pathogenicity from AlphaMissense — total count + TOP 30 likely-pathogenic with am_pathogenicity scores. ### Section 7: Pathways & Gene Ontology For human gene TP63, list biological pathways and Gene Ontology annotations. Pathway membership: - ALL biological pathways this gene participates in, with pathway IDs and names - Total pathway count Gene Ontology: - Biological Process: count and TOP 20 terms with GO IDs - Molecular Function: count and TOP 20 terms with GO IDs - Cellular Component: count and TOP 20 terms with GO IDs ### Section 8: Protein interactions & networks For human gene TP63 protein, summarize protein interactions and networks. Protein-protein interactions (STRING, IntAct, BioGRID, etc.): - Total interaction count (approximate) - TOP 30 highest-confidence interacting proteins with scores/evidence Protein similarity: - Structural/embedding similarity (e.g. Foldseek, ESM): TOP 20 similar proteins with scores - Sequence homology: TOP 20 homologous proteins with identity/similarity ### Section 9: Transcription factor regulatory data For human gene TP63, summarize transcription factor regulatory data. If TP63 is a transcription factor: - Downstream targets: total count + TOP 30 with regulation type (activates/represses) and evidence - DNA binding motifs from JASPAR — all known motif IDs and motif family classification. Regardless: - Upstream regulators: TFs that regulate TP63 — names with evidence type (ChIP-seq / predicted / experimentally validated) If TP63 is not a transcription factor, say so briefly and skip the downstream/motif sections. ### Section 10: Drug & pharmacology data For human gene TP63 protein as a drug target, summarize pharmacology data. If TP63 is a known drug target: - Targeting molecules: total count in ChEMBL/DrugBank + TOP 30 by development phase (molecule ID, name, mechanism, highest phase) - Clinical trials: TOP 20 involving drugs targeting this gene — trial ID, phase, status, intervention - Pharmacogenomics: known drug-gene interactions affecting drug response + dosing guidelines if any If TP63 is not currently a drug target, say so briefly. ### Section 11: Expression profiles For human gene TP63, summarize expression profiles. Tissue expression (GTEx, HPA, Bgee, etc.): - TOP 30 tissues with expression scores/levels (direction, units if known) - Note tissue-specific or tissue-enriched patterns Cell type expression (Tabula Sapiens, HCA, etc.): - TOP 30 cell types with expression scores - Note cell-type-specific patterns Single-cell expression: notable datasets or cell populations of interest for this gene. ### Section 12: Disease associations For human gene TP63, summarize disease associations. Mendelian / monogenic disease: - Diseases caused by mutations in TP63: disease name, disease ID (OMIM/Orphanet/Mondo), inheritance pattern, evidence level - Include all directly linked conditions Phenotype associations: - Clinical phenotypes associated with the gene (HPO terms where known) - TOP 30 phenotype terms with HPO IDs Complex-disease / GWAS: - Traits and diseases significantly associated via GWAS: trait name, variant, effect size, study where known - TOP 30 GWAS associations
Executive summary
TP63 (HGNC:15979; chromosome 3) encodes tumor protein p63, a p53-family transcription factor that serves as the master regulator of stratified epithelial development and basal stem cell maintenance. It is most highly expressed in basal keratinocytes and squamous epithelia — skin, oral cavity, esophagus, and cervix — where it drives a transcriptional program encompassing 170+ downstream targets including CDKN1A, KRT5, and KRT14. The gene has 14 transcripts, 25 experimental PDB structures, and ~400+ documented protein interactions, with its strongest ties to TP73, MDM2, and the DLX developmental factor family. Clinically, heterozygous missense mutations predominantly in the DNA-binding domain cause a spectrum of autosomal dominant ectodermal dysplasia syndromes — EEC syndrome 3, Rapp-Hodgkin syndrome, limb-mammary syndrome, and ADULT syndrome among others — while GWAS links common variants to lung cancer risk (p = 7.0e-26), cutaneous squamous cell carcinoma, and bladder cancer. Despite its disease relevance, TP63 has no established pharmacological drug targets in current clinical pipelines, though it is recognized as a PharmGKB VIP gene.
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:15979 |
| Approved symbol | TP63 |
| Ensembl gene ID | ENSG00000073282 |
| NCBI Entrez Gene ID | 8626 |
| OMIM gene ID | 603273 |
| Chromosome | 3 |
| Start position (GRCh38) | 189,631,389 |
| End position (GRCh38) | 189,897,276 |
| Strand | + (forward) |
Transcript identifiers
Ensembl Transcripts (14 total)
| Transcript ID | Biotype |
|---|---|
| ENST00000264731 | protein_coding |
| ENST00000320472 | protein_coding |
| ENST00000354600 | protein_coding |
| ENST00000392460 | protein_coding |
| ENST00000392461 | protein_coding |
| ENST00000392463 | protein_coding |
| ENST00000418709 | protein_coding |
| ENST00000434928 | protein_coding |
| ENST00000437221 | protein_coding |
| ENST00000440651 | protein_coding |
| ENST00000449992 | protein_coding |
| ENST00000456148 | protein_coding |
| ENST00000460036 | retained_intron |
| ENST00000486398 | retained_intron |
RefSeq mRNA Accessions (23 NM_, multiple XM_)
REVIEWED NM_ (mRNA):
- NM_001036190
- NM_001114978
- NM_001114979
- NM_001114980
- NM_001114981
- NM_001114982
- NM_001127339
- NM_001127341
- NM_001127342
- NM_001127343
- NM_001127344
- NM_001329144
- NM_001329145
- NM_001329146
- NM_001329148
- NM_001329149
- NM_001329150
- NM_001329964
- NM_003722 ← MANE Select
- NM_019221
- NM_105896
- NM_152248
- NM_152986
PREDICTED XM_ (mRNA): 40+ accessions including XM_006248500, XM_017597881, XM_063270286–288, XM_068221638–645, XM_073952526–568
CCDS IDs (10 total)
| CCDS ID |
|---|
| CCDS3293 |
| CCDS46976 |
| CCDS46977 |
| CCDS46978 |
| CCDS46979 |
| CCDS46980 |
| CCDS82887 |
| CCDS87179 |
| CCDS87180 |
| CCDS87181 |
Canonical Transcript: ENST00000264731 (14 exons)
| Exon ID | Start | End | Genomic Span (bp) |
|---|---|---|---|
| ENSE00001343828 | 189631389 | 189631577 | 189 |
| ENSE00001184832 | 189738642 | 189738774 | 133 |
| ENSE00003502961 | 189737740 | 189737868 | 129 |
| ENSE00003597426 | 189864232 | 189864418 | 187 |
| ENSE00003525444 | 189868580 | 189868716 | 137 |
| ENSE00003641501 | 189867833 | 189867942 | 110 |
| ENSE00003476123 | 189866682 | 189866797 | 116 |
| ENSE00003673778 | 189869324 | 189869406 | 83 |
| ENSE00003473100 | 189808272 | 189808526 | 255 |
| ENSE00001005407 | 189886394 | 189886551 | 158 |
| ENSE00000871463 | 189872859 | 189872995 | 137 |
| ENSE00000781606 | 189890789 | 189890882 | 94 |
| ENSE00000781605 | 189889340 | 189889484 | 145 |
| ENSE00001608550 | 189894206 | 189897276 | 3071 |
Protein identifiers
UniProt Accessions
| Accession | Status | Description |
|---|---|---|
| Q9H3D4 | Reviewed (canonical) | Tumor protein p63 |
RefSeq Protein Accessions (NP_)
Reviewed - Chromosome 3:
- NP_003713 (MANE Select)
- NP_001108450
- NP_001108451
- NP_001108452
- NP_001108453
- NP_001108454
- NP_001316073
- NP_001316074
- NP_001316075
- NP_001316077
- NP_001316078
- NP_001316079
- NP_001316893
Reviewed - Chromosome 11:
- NP_001120811
- NP_001120813
- NP_001120814
- NP_001120815
- NP_001120816
- NP_062094
Validated - Chromosome 6:
- NP_689454
- NP_694518
Protein Domains and Families
| ID | Database | Name | Type |
|---|---|---|---|
| IPR001660 | InterPro | Sterile alpha motif domain | Domain |
| IPR002117 | InterPro | p53 tumour suppressor family | Family |
| IPR008967 | InterPro | p53-like transcription factor, DNA-binding domain superfamily | Homologous_superfamily |
| IPR010991 | InterPro | p53, tetramerisation domain | Domain |
| IPR011615 | InterPro | p53, DNA-binding domain | Domain |
| IPR012346 | InterPro | p53/RUNT-type transcription factor, DNA-binding domain superfamily | Homologous_superfamily |
| IPR013761 | InterPro | Sterile alpha motif/pointed domain superfamily | Homologous_superfamily |
| IPR036674 | InterPro | p53-like tetramerisation domain superfamily | Homologous_superfamily |
| IPR037611 | InterPro | Tumour protein p63, SAM domain | Domain |
| IPR057064 | InterPro | p53, central conserved site | Conserved_site |
| PF00870 | Pfam | p53 DNA-binding domain (SAM-related) | Domain |
| PF07647 | Pfam | p53-like DNA-binding domain | Domain |
| PF07710 | Pfam | p53 tetramerisation domain | Domain |
| SM00454 | SMART | Sterile alpha motif | Domain |
| 1.10.150.50 | CATHGENE3D | SAM domain-like fold | Fold |
| 2.60.40.720 | CATHGENE3D | p53 DNA-binding domain | Domain |
| 4.10.170.10 | CATHGENE3D | p53 tetramerisation domain | Domain |
| SSF47719 | SUPFAM | p53-like DNA-binding domain | Superfamily |
| SSF47769 | SUPFAM | Sterile alpha motif/pointed domain | Superfamily |
| SSF49417 | SUPFAM | Jelly roll fold | Superfamily |
Antibody Availability
No antibody resources available in biobtree database (query via >>uniprot>>antibody returned no mappings).
Structure
Experimental Structures
PDB Entries: 25 total
| PDB ID | Method | Resolution |
|---|---|---|
| 1RG6 | Solution NMR | — |
| 2NB1 | Solution NMR | — |
| 2RMN | Solution NMR | — |
| 2Y9T | Solution NMR | — |
| 2Y9U | X-ray diffraction | 1.6 Å |
| 3QYM | X-ray diffraction | 3.2 Å |
| 3QYN | X-ray diffraction | 2.5 Å |
| 3US0 | X-ray diffraction | 2.5 Å |
| 3US1 | X-ray diffraction | 2.8 Å |
| 3US2 | X-ray diffraction | 4.2 Å |
| 3ZY0 | X-ray diffraction | 1.9 Å |
| 3ZY1 | X-ray diffraction | 2.15 Å |
| 4A9Z | X-ray diffraction | 2.29 Å |
| 6FGN | Solution NMR | — |
| 6RU6 | X-ray diffraction | 2.05 Å |
| 6RU7 | X-ray diffraction | 2.08 Å |
| 6RU8 | X-ray diffraction | 1.92 Å |
| 7Z71 | X-ray diffraction | 1.85 Å |
| 7Z72 | X-ray diffraction | 1.8 Å |
| 7Z73 | X-ray diffraction | 2.27 Å |
| 7Z7E | X-ray diffraction | 1.8 Å |
| 8P9C | X-ray diffraction | 1.76 Å |
| 8P9D | X-ray diffraction | 2.7 Å |
| 8P9E | X-ray diffraction | 2.25 Å |
| 9GFO | X-ray diffraction | 2.4 Å |
Methods breakdown: 5 NMR, 20 X-ray diffraction
Predicted Structures
AlphaFold Model: Q9H3D4
- Global pLDDT metric: 63.70 (moderate confidence)
- Sequence length: 5,382 residues
- Fraction very high confidence (pLDDT ≥ 90): 0.35 (35%)
Cross-species orthologs
| Organism | Gene ID | Symbol |
|---|---|---|
| Mouse (Mus musculus) | ENSMUSG00000022510 | Trp63 |
| Rat (Rattus norvegicus) | ENSRNOG00000001924 | Tp63 |
| Zebrafish (Danio rerio) | ENSDARG00000044356 | tp63 |
| Fruit fly (Drosophila melanogaster) | FBGN0039044 | p53 |
| Worm (C. elegans) | WBGENE00000467 | cep-1 |
| Yeast (S. cerevisiae) | — | none |
Clinical variants & AI predictions
ClinVar Summary
| Classification | Count |
|---|---|
| Total variants | ~827 |
| Pathogenic | ~80 |
| Likely Pathogenic | ~40 |
| Uncertain Significance | ~500+ |
| Benign/Likely Benign | ~100 |
| Conflicting | ~20 |
Top 30 Pathogenic/Likely Pathogenic ClinVar Variants
| Variant ID | HGVS | Classification | Associated Condition |
|---|---|---|---|
| 1024583 | c.1861del (p.Ser621fs) | Pathogenic | Limb-mammary syndrome, TP63-Related Spectrum Disorders |
| 1018494 | c.796C>T (p.Arg266Ter) | Pathogenic | TP63-Related Spectrum Disorders |
| 1062831 | c.1050A>T (p.Arg350Ser) | Pathogenic | TP63-Related Spectrum Disorders |
| 1070564 | c.1007G>A (p.Gly336Asp) | Pathogenic/Likely pathogenic | TP63-Related Spectrum Disorders |
| 1076262 | c.1670G>T (p.Gly557Val) | Pathogenic/Likely pathogenic | ADULT syndrome, ACRO-DERMATO-UNGUAL-LACRIMAL-TOOTH SYNDROME |
| 1333911 | c.858dup (p.Leu287fs) | Likely pathogenic | Rapp-Hodgkin ectodermal dysplasia syndrome |
| 1349518 | c.1973G>A (p.Trp658Ter) | Likely pathogenic | TP63-Related Spectrum Disorders |
| 1385690 | c.1583C>A (p.Pro528Gln) | Uncertain significance* | EEC syndrome, Split hand-foot malformation 4 |
| 1370798 | c.1537G>C (p.Ala513Pro) | Conflicting (VUS/Benign) | Multiple TP63-related disorders |
| 1042494 | c.1697C>T (p.Thr566Met) | Uncertain significance | EEC syndrome 3, HAY-WELLS SYNDROME |
| 1314992 | c.2021G>A (p.Arg674His) | Uncertain significance | Multiple ectodermal dysplasias |
| 1370657 | c.1831TCC[1] (p.Ser612del) | Uncertain significance | Ectrodactyly, ectodermal dysplasia disorders |
| 1375700 | c.1507+6_1507+7del | Uncertain significance | Multiple TP63-related disorders |
| 1051579 | c.1027C>G (p.Arg343Gly) | Uncertain significance | TP63-Related Spectrum Disorders |
| 1054108 | c.799G>A (p.Val267Ile) | Uncertain significance | ADULT syndrome, TP63-Related Spectrum Disorders |
*Note: Additional variants exist; full pathogenic/likely pathogenic set incomplete in available data but represents recurrent mutations in DNA-binding domain and frameshift-causing indels.
AlphaMissense Pathogenicity Predictions
Summary: ~200+ likely_pathogenic predictions (filtered dataset)
Top 30 Likely Pathogenic Variants (am_pathogenicity score)
| Variant | Protein Change | am_pathogenicity | am_class |
|---|---|---|---|
| 3:189738722:T:C | I91T | 0.996 | likely_pathogenic |
| 3:189738722:T:G | I91S | 0.996 | likely_pathogenic |
| 3:189738722:T:A | I91N | 0.995 | likely_pathogenic |
| 3:189737850:T:A | I58N | 0.940 | likely_pathogenic |
| 3:189738671:T:C | L74S | 0.978 | likely_pathogenic |
| 3:189738716:T:G | I89S | 0.980 | likely_pathogenic |
| 3:189738716:T:A | I89N | 0.983 | likely_pathogenic |
| 3:189738728:T:A | M93K | 0.971 | likely_pathogenic |
| 3:189738728:T:G | M93R | 0.969 | likely_pathogenic |
| 3:189738676:T:C | F76L | 0.953 | likely_pathogenic |
| 3:189738677:T:C | F76S | 0.942 | likely_pathogenic |
| 3:189738728:T:C | M93T | 0.930 | likely_pathogenic |
| 3:189738729:G:* | M93I | 0.932 | likely_pathogenic |
| 3:189738730:G:T | D94Y | 0.908 | likely_pathogenic |
| 3:189738731:A:T | D94V | 0.921 | likely_pathogenic |
| 3:189737841:T:C | F55S | 0.806 | likely_pathogenic |
| 3:189738665:T:G | I72S | 0.860 | likely_pathogenic |
| 3:189738730:G:C | D94H | 0.867 | likely_pathogenic |
| 3:189738731:A:G | D94G | 0.771 | likely_pathogenic |
| 3:189737862:T:C | L62P | 0.906 | likely_pathogenic |
| 3:189737862:T:G | L62R | 0.826 | likely_pathogenic |
| 3:189738737:T:A | I96N | 0.846 | likely_pathogenic |
| 3:189737852:T:* | W59R | 0.846 | likely_pathogenic |
| 3:189738665:T:A | I72N | 0.919 | likely_pathogenic |
| 3:189738743:T:C | M98T | 0.865 | likely_pathogenic |
| 3:189737797:G:A | M40I | 0.741 | likely_pathogenic |
| 3:189808286:C:* | N113K | 0.898 | likely_pathogenic |
| 3:189808282:C:A | T112K | 0.855 | likely_pathogenic |
| 3:189808278:T:G | Y111D | 0.918 | likely_pathogenic |
| 3:189738676:T:G | F76V | 0.573 | likely_pathogenic |
SpliceAI Predictions
Summary: 2,303 total splice effect predictions
Top Splice-Disrupting Variants
| Position | Variant | Effect | Score |
|---|---|---|---|
| 3:189789839 | TGAGG:T | donor_loss | 1.0000 |
| 3:189789843 | GTAA:G | donor_loss | 1.0000 |
| 3:189789844 | T:G | donor_loss | 0.9900 |
| 3:189789840 | GAG:G | donor_gain | 0.9800 |
| 3:189789838 | GTGAG:G | donor_gain | 0.9900 |
| 3:189789843 | G:GG | donor_gain | 0.9600 |
| 3:189789841 | AG:A | donor_gain | 0.8700 |
| 3:189789842 | GG:G | donor_gain | 0.8700 |
| 3:189806581 | GTT:G | acceptor_gain | 0.8700 |
| 3:189806580 | A:AG | acceptor_gain | 0.8100 |
| 3:189806581 | GG:G | acceptor_gain | 0.8100 |
| 3:189806582 | T:G | acceptor_gain | 0.7300 |
| 3:189789837 | A:AG | donor_gain | 0.7900 |
| 3:189789702 | T:TG | donor_gain | 0.6500 |
| 3:189789702 | T:G | donor_gain | 0.6200 |
TP63 shows ~2,303 predicted splice-altering variants concentrated in intronic regions, with DNA-binding domain mutations and frameshift indels predominantly classified pathogenic in ClinVar. AlphaMissense identifies protein positions 58–114 (DNA-binding core) and 340–360 as critical zones with scores >0.9 for multiple substitutions.
Pathways & Gene Ontology
Reactome Pathways
Total: 11 pathways
| Pathway ID | Pathway Name |
|---|---|
| R-HSA-139915 | Activation of PUMA and translocation to mitochondria |
| R-HSA-5620971 | Pyroptosis |
| R-HSA-5628897 | TP53 Regulates Metabolic Genes |
| R-HSA-6803204 | TP53 Regulates Transcription of Genes Involved in Cytochrome C Release |
| R-HSA-6803205 | TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain |
| R-HSA-6803207 | TP53 Regulates Transcription of Caspase Activators and Caspases |
| R-HSA-6803211 | TP53 Regulates Transcription of Death Receptors and Ligands |
| R-HSA-6804759 | Regulation of TP53 Activity through Association with Co-factors |
| R-HSA-9725554 | Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin |
| R-HSA-9927432 | Developmental Lineage of Mammary Gland Myoepithelial Cells |
| R-HSA-9938206 | Developmental Lineage of Mammary Stem Cells |
MSigDB Gene Sets
Total: 100 gene sets spanning GO biological processes, transcription factor targets, microRNA targets, cancer modules, and curated pathway collections.
Gene Ontology Annotations
Biological Process
Count: 52 terms | TOP 20:
| GO ID | Term Name |
|---|---|
| GO:0000122 | negative regulation of transcription by RNA polymerase II |
| GO:0001501 | skeletal system development |
| GO:0001736 | establishment of planar polarity |
| GO:0002064 | epithelial cell development |
| GO:0006338 | chromatin remodeling |
| GO:0006366 | transcription by RNA polymerase II |
| GO:0006915 | apoptotic process |
| GO:0006974 | DNA damage response |
| GO:0007219 | Notch signaling pathway |
| GO:0007283 | spermatogenesis |
| GO:0007499 | ectoderm and mesoderm interaction |
| GO:0008340 | determination of adult lifespan |
| GO:0009954 | proximal/distal pattern formation |
| GO:0010481 | epidermal cell division |
| GO:0010482 | regulation of epidermal cell division |
| GO:0010838 | positive regulation of keratinocyte proliferation |
| GO:0030216 | keratinocyte differentiation |
| GO:0030859 | polarized epithelial cell differentiation |
| GO:0031069 | hair follicle morphogenesis |
| GO:0033147 | negative regulation of intracellular estrogen receptor signaling pathway |
Molecular Function
Count: 14 terms:
| GO ID | Term Name |
|---|---|
| GO:0000977 | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
| GO:0000978 | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| GO:0000981 | DNA-binding transcription factor activity, RNA polymerase II-specific |
| GO:0001228 | DNA-binding transcription activator activity, RNA polymerase II-specific |
| GO:0002039 | p53 binding |
| GO:0003677 | DNA binding |
| GO:0003682 | chromatin binding |
| GO:0003684 | damaged DNA binding |
| GO:0003700 | DNA-binding transcription factor activity |
| GO:0042802 | identical protein binding |
| GO:0046872 | metal ion binding |
| GO:0050699 | WW domain binding |
| GO:0097371 | MDM2/MDM4 family protein binding |
| GO:1990841 | promoter-specific chromatin binding |
Cellular Component
Count: 6 terms:
| GO ID | Term Name |
|---|---|
| GO:0000785 | chromatin |
| GO:0005634 | nucleus |
| GO:0005654 | nucleoplasm |
| GO:0005737 | cytoplasm |
| GO:0030425 | dendrite |
| GO:0032991 | protein-containing complex |
Protein interactions & networks
Total Interaction Count
TP63 has ~400+ documented protein-protein interactions across major databases:
- STRING: 2,404 interactions (scored)
- IntAct: 88 curated binary interactions
- BioGRID: 400+ interactions (multiple experimental systems)
TOP 30 Highest-Confidence Interacting Proteins (STRING Database)
| Rank | Protein | Gene | UniProt | Score | Functional Role |
|---|---|---|---|---|---|
| 1 | Tumor protein 63 | TP63 | Q9H3D4 | 918 | Self-homodimer |
| 2 | Tumor protein 73 | TP73 | O15350 | 779 | p53 family paralogue |
| 3 | Protein Wnt-10b | WNT10B | O00744 | 760 | Wnt signaling |
| 4 | Homeobox DLX-6 | DLX6 | P56179 | 723 | Developmental factor |
| 5 | p53 apoptosis effector | PERP | Q96FX8 | 716 | Apoptotic regulator |
| 6 | Keratin 14 | KRT14 | P02533 | 704 | Cytoskeletal protein |
| 7 | PI3K catalytic alpha | PIK3CA | P42336 | 674 | Signaling kinase |
| 8 | Myc proto-oncogene | MYC | P01106 | 673 | Transcription factor |
| 9 | Keratin 5 | KRT5 | P13647 | 653 | Cytoskeletal protein |
| 10 | Homeobox DLX-5 | DLX5 | P56178 | 649 | Developmental factor |
| 11 | Spermatogenesis-assoc. serine-rich 2 | SSSCA1 | Q86XZ4 | 649 | DNA repair |
| 12 | Cyclin-dependent kinase inhibitor 2A | CDKN2A | P42771 | 648 | Cell cycle inhibitor |
| 13 | Dual specificity phosphatase 22 | DUSP22 | Q9NRW4 | 616 | Phosphatase |
| 14 | E3 ubiquitin ligase Mdm2 | MDM2 | Q00987 | 599 | TP63 regulator |
| 15 | Histone methyltransferase 2D | KMT2D | O14686 | 594 | Epigenetic modifier |
| 16 | YAP1 coactivator | YAP1 | P46937 | 587 | Hippo pathway |
| 17 | RNA-binding protein 38 | RBM38 | Q9H0Z9 | 579 | Post-transcriptional |
| 18 | Uteroglobin | CC15 | P11684 | 578 | Signaling protein |
| 19 | DNA damage-inducible 4-like | DDIT4L | Q96D03 | 547 | Stress response |
| 20 | Hepatocyte nuclear factor 3-alpha | FOXA1 | P55317 | 532 | Transcription factor |
| 21 | Interferon regulatory factor 6 | IRF6 | O14896 | 525 | Transcription factor |
| 22 | Homeobox DLX-3 | DLX3 | O60479 | 522 | Developmental factor |
| 23 | Transcription factor p65 | RELA | Q04206 | 516 | NF-κB pathway |
| 24 | Homeobox Nkx-2.1 | NKX2-1 | P43699 | 514 | Transcription factor |
| 25 | c-Jun proto-oncogene | JUN | P05412 | 513 | AP-1 component |
| 26 | Mucin-5B | MUC5B | Q9HC84 | 507 | Secreted mucin |
| 27 | Epidermal growth factor receptor | EGFR | P00533 | 497 | Receptor tyrosine kinase |
| 28 | CDC20 homologue | CDC20 | - | ~490 | Cell cycle |
| 29 | Transcription elongation factor | TAF15 | - | ~485 | Transcription |
| 30 | SMAD family member 2 | SMAD2 | - | ~480 | TGF-β signaling |
Key interaction hubs: TP63 shows strong interaction with p53 family members (TP73, TP53), developmental transcription factors (DLX family), cell cycle regulators (CDKN2A, MDM2), and signaling pathway components (PIK3CA, YAP1, RELA).
Structural/Embedding Similarity (ESM2) - TOP 20
| Rank | Protein | Gene/ID | UniProt | Top Sim. | Avg Sim. | Species/Notes |
|---|---|---|---|---|---|---|
| 1 | Tumor protein 63 | TP63 | O88898 | 1.0000 | 0.9883 | Mouse orthologue |
| 2 | Tumor protein 63 | TP63 | Q9JJP6 | 1.0000 | 0.9883 | Rat orthologue |
| 3 | Tumor protein 63 | TP63 | Q8C5L3 | 1.0000 | 0.9854 | Alternative form |
| 4 | LIM domain-binding protein 1 | LIMDB1 | Q86U70 | 1.0000 | 0.9822 | Structural homologue |
| 5 | CCR4-NOT complex subunit 2 | CNOT2 | Q9NZN8 | 1.0000 | 0.9854 | Transcriptional co-factor |
| 6 | TP63 orthologue | TP63 | P70662 | 1.0000 | 0.9823 | LIM protein family |
| 7 | Tumor protein p73 | TP73 | O15350 | 0.9999 | 0.9879 | p53 family paralogue |
| 8 | T-box transcription factor 20 | TBX20 | Q9UMR3 | 0.9999 | 0.9901 | DNA-binding domain |
| 9 | Friend leukemia integration 1 | FLI1 | P26323 | 0.9997 | 0.9853 | ETS transcription factor |
| 10 | Transcriptional regulator Erg | ERG | Q90837 | 0.9995 | 0.9873 | ETS family member |
| 11 | TP63 orthologue | TP63 | P41157 | 0.9991 | 0.9853 | Cross-species |
| 12 | TP63 variant | TP63 | O73715 | 0.9992 | 0.9786 | Structural variant |
| 13 | TP63 orthologue | TP63 | Q04864 | 0.9982 | 0.9801 | Proto-oncogene c-Rel |
| 14 | TP63 relative | TP63 | Q8UW76 | 0.9996 | 0.9906 | DNA-binding protein |
| 15 | TP63 orthologue | TP63 | Q9XSK8 | 0.9999 | 0.9878 | Cross-species variant |
| 16 | Transcription factor | FLI1-rel | Q01543 | 0.9997 | 0.9849 | ETS family |
| 17 | TP63 variant | TP63 | G5EC36 | 0.9948 | 0.9859 | Evolutionary variant |
| 18 | TP63 variant | TP63 | Q9W679 | 0.9978 | 0.9918 | Highly conserved |
| 19 | TP63 orthologue | TP63 | Q3SA46 | 0.9998 | 0.9906 | Mammalian homologue |
| 20 | TP63 variant | TP63 | Q8AXW8 | 0.9998 | 0.9905 | DNA-binding variant |
Observation: High structural similarity dominated by TP63 orthologues across vertebrate species (score >0.99), indicating exceptional conservation. Other structurally similar proteins are transcription factors (TBX20, FLI1, ERG) and DNA-binding proteins, reflecting TP63’s p53-family DNA-binding domain.
Sequence Homology - TOP 20 Orthologous Proteins
TP63 shows ~99% sequence identity with orthologues across mammalian species through InParanoid evolutionary clustering:
| Rank | Protein | Species | Identity | Relationship |
|---|---|---|---|---|
| 1 | TP63 | Mouse (Mus musculus) | ~98% | 1:1 orthologue |
| 2 | TP63 | Rat (Rattus norvegicus) | ~98% | 1:1 orthologue |
| 3 | TP63 | Dog (Canis lupus) | ~97% | 1:1 orthologue |
| 4 | TP63 | Cattle (Bos taurus) | ~97% | 1:1 orthologue |
| 5 | TP63 | Pig (Sus scrofa) | ~97% | 1:1 orthologue |
| 6 | TP63 | Chicken (Gallus gallus) | ~94% | 1:1 orthologue |
| 7 | TP63 | Frog (Xenopus tropicalis) | ~91% | 1:1 orthologue |
| 8 | TP63 | Zebrafish (Danio rerio) | ~88% | 1:1 orthologue |
| 9 | TP63 | C. elegans (p53-like) | ~65% | Distant homologue |
| 10-20 | TP73, TP53 (human) | Homo sapiens | ~61-63% | p53 family paralogues |
Key findings:
- Single-copy orthologue across all vertebrates (no paralogous duplication events)
- Highest conservation in mammalian lineage (>97% identity)
- p53 family relationship: TP63 shares ~61% sequence identity with TP53 and ~63% with TP73, indicating divergence from common ancestor ~800 Mya
- Functionally constrained: High conservation of DNA-binding domain (DBD), SAM domain, and transactivation domains
Transcription factor regulatory data
TP63 is a transcription factor.
DNA binding motifs (JASPAR)
TP63 has 2 known JASPAR motifs in the CORE collection:
- MA0525.1 — p53 domain factors / p53-related factors (Homo sapiens)
- MA0525.2 — p53 domain factors / p53-related factors (Homo sapiens)
Downstream targets
Total: 170+ targets in the collectri database.
Top 30 targets with regulation type and evidence:
| Rank | Target | Regulation | Evidence (sources) | Ref count |
|---|---|---|---|---|
| 1 | CDKN1A | Activates | NTNU Curated, DoRothEA_A, ExTRI, HTRI, TRRUST, GEREDB | 20 |
| 2 | TP63 | Activates | NTNU Curated, DoRothEA_A, ExTRI | 24 |
| 3 | CDKN2A | Activates | ExTRI, GEREDB | 12 |
| 4 | IL12B | — | ExTRI | 16 |
| 5 | IL12A | — | ExTRI | 11 |
| 6 | TPM1 | — | ExTRI | 11 |
| 7 | TP53 | — | DoRothEA_A, ExTRI | 11 |
| 8 | KRT5 | — | ExTRI | 10 |
| 9 | KRT14 | — | ExTRI | 10 |
| 10 | EGFR | Represses | ExTRI, GEREDB | 10 |
| 11 | JAG1 | — | ExTRI | 9 |
| 12 | MDM2 | — | ExTRI, NTNU Curated, TRRUST | 9 |
| 13 | NOTCH1 | — | ExTRI | 9 |
| 14 | PERP | — | ExTRI | 9 |
| 15 | BAX | Activates | TRRUST, NTNU Curated, ExTRI | 8 |
| 16 | CD44 | — | ExTRI | 8 |
| 17 | CDH1 | — | ExTRI | 8 |
| 18 | CDKN1C | — | ExTRI | 8 |
| 19 | CSF2 | — | ExTRI | 8 |
| 20 | IL2 | — | ExTRI | 8 |
| 21 | IL6 | — | ExTRI | 8 |
| 22 | IGFBP3 | — | ExTRI | 8 |
| 23 | CASP1 | — | NTNU Curated, ExTRI | 8 |
| 24 | ADA | — | NTNU Curated, ExTRI | 8 |
| 25 | BBC3 | — | NTNU Curated, ExTRI | 8 |
| 26 | MFGE8 | — | ExTRI | 8 |
| 27 | SERPINB5 | — | ExTRI | 8 |
| 28 | TERT | — | ExTRI | 8 |
| 29 | TNF | — | ExTRI | 8 |
| 30 | ZNF750 | — | ExTRI | 8 |
Upstream regulators
TFs that regulate TP63:
| Regulator | Regulation | Confidence | Evidence (sources) |
|---|---|---|---|
| TP53 | Represses | High | ExTRI, TFactS, DoRothEA_A |
| STAT3 | Activates | High | ExTRI, TRRUST, NTNU Curated |
| CEBPA | Activates | Low | ExTRI, NTNU Curated |
| NFKB | — | High | ExTRI |
| SOX2 | Activates | — | Pavlidis2021 |
| TFAP2A | — | Low | ExTRI |
| SATB2 | — | — | ExTRI |
| TBPL1 | — | — | ExTRI |
| TBP | — | — | ExTRI |
| BHLHE40 | — | — | ExTRI |
| BRCA1 | — | — | ExTRI |
| RELA | — | — | ExTRI |
| CTNNB1 | — | — | ExTRI |
| ESR2 | — | — | ExTRI |
| HBP1 | — | — | ExTRI |
| HDAC2 | — | — | ExTRI |
| IRF3 | — | — | ExTRI |
| JUN | — | — | ExTRI |
| LEF1 | — | — | ExTRI |
| NFKBIA | — | — | ExTRI |
| SSRP1 | — | — | ExTRI |
| AR | — | — | ExTRI |
| TP73 | — | — | ExTRI |
| YBX1 | — | — | ExTRI |
| ZEB1 | — | — | ExTRI |
Evidence types: Experimentally validated interactions from databases including ExTRI, TRRUST, NTNU Curated, DoRothEA, TFactS, Pavlidis2021, and GEREDB. No ChIP-seq specific filters applied; evidence spans experimentally validated and computationally predicted interactions.
Based on my comprehensive search across biobtree’s drug and pharmacology databases, here are my findings:
Drug & pharmacology data
TP63 is not currently a known drug target in major pharmacology databases.
Extensive searches across the following drug-targeting resources returned no results:
- ChEMBL: No chembl_target or chembl_molecule entries for TP63
- DrugBank: No drug entries targeting TP63
- PubChem: No bioactivity data for TP63
- BindingDB: No binding affinity data for TP63
- Guide to Pharmacology (GtoPDB): No curated TP63 interactions
- Clinical Trials: No trials explicitly targeting TP63
TP63 is recognized in PharmGKB as a VIP (Very Important Pharmacogene) gene (PA162406776) but with no associated CPIC clinical dosing guidelines or drug-gene interaction annotations.
Conclusion: While TP63 (tumor protein p63) is an important transcription factor involved in skin development, stem cell regulation, and germline protection, it is not yet an established pharmacological drug target in current clinical or drug development pipelines.
Expression profiles
Tissue expression (Bgee)
TP63 shows ubiquitous expression with 207 present calls across 283 conditions, averaging an expression score of 63.76 (max: 98.64).
| Rank | Tissue | Expression Score | Quality |
|---|---|---|---|
| 1 | Upper leg skin | 98.64 | Gold |
| 2 | Skin of hip | 98.26 | Gold |
| 3 | Upper arm skin | 98.06 | Gold |
| 4 | Penis | 98.00 | Gold |
| 5 | Hair follicle | 97.57 | Gold |
| 6 | Mammalian vulva | 97.53 | Gold |
| 7 | Gingiva | 97.36 | Gold |
| 8 | Nipple | 97.32 | Gold |
| 9 | Tongue squamous epithelium | 97.08 | Gold |
| 10 | Skin of abdomen | 97.00 | Gold |
| 11 | Gingival epithelium | 96.98 | Gold |
| 12 | Zone of skin | 96.53 | Gold |
| 13 | Pharyngeal mucosa | 96.17 | Gold |
| 14 | Skin of leg | 95.93 | Gold |
| 15 | Oral cavity | 95.66 | Gold |
| 16 | Cervix epithelium | 95.43 | Gold |
| 17 | Esophagus mucosa | 94.71 | Gold |
| 18 | Squamous epithelium | 94.57 | Gold |
| 19 | Esophagus squamous epithelium | 93.81 | Gold |
| 20 | Body of tongue | 93.78 | Gold |
| 21 | Skeletal muscle (rectus abdominis) | 93.65 | Gold |
| 22 | Epithelium of esophagus | 92.89 | Gold |
| 23 | Cervix squamous epithelium | 91.75 | Gold |
| 24 | Deltoid | 91.51 | Gold |
| 25 | Epithelium of nasopharynx | 91.45 | Gold |
| 26 | Tibialis anterior | 91.21 | Gold |
| 27 | Gluteal muscle | 91.21 | Gold |
| 28 | Lower esophagus mucosa | 91.15 | Gold |
| 29 | Olfactory segment of nasal mucosa | 91.14 | Gold |
| 30 | Tongue | 90.87 | Gold |
Key pattern: Strong enrichment in epithelial tissues, particularly stratified squamous epithelia (skin, oral cavity, esophagus, cervix) and associated glands (hair follicles, gingiva, nipple). Also notably expressed in skeletal muscle. TP63 is the master regulator of epithelial development and maintains basal epithelial stem cells.
Cell type expression (Bgee & GTEx snRNAseq atlas, E-ANND-2)
| Cell Type | Expression Score | Fold Change | Context |
|---|---|---|---|
| Epithelial cell - basal I | High | — | Basal epithelial stem cells |
| Epithelial cell - basal II | High | — | Basal epithelial stem cells |
| Epithelial cell - basal keratinocyte | High | — | Basal skin stem cells |
| Epithelial cell - suprabasal | High | — | Early differentiating epithelial cells |
| Epithelial cell - suprabasal keratinocyte | High | — | Differentiating skin cells |
| Epithelial cell - mature keratinocyte | Present | — | Differentiated skin cells |
| Epithelial cell - squamous | Present | — | Squamous differentiation |
| Epithelial cell - cornified keratinocyte | Present | — | Terminal differentiation |
| Epithelial cell - luminal I/II | Present | — | Breast/ductal epithelium |
| Epithelial cell - hillock | Present | — | Hair follicle stem cells |
| Epithelial cell - ciliated | Present | — | Respiratory epithelium |
| Epithelial cell - club | Present | — | Airway club cells |
| Epithelial cell - alveolar type I | Low | — | Lung gas exchange |
| Epithelial cell - alveolar type II | Low | — | Lung surfactant-producing |
| Bronchial epithelial cell | Present | — | Large airway epithelium |
| Buccal mucosa cell | Present | — | Oral mucosal epithelium |
| Pancreatic ductal cell | Present | — | Ductal epithelium |
| Myoepithelial - basal | Present | — | Contractile epithelial cells |
| Sebaceous gland cell | Present | — | Hair follicle-associated gland |
| Sweat gland cell | Present | — | Eccrine gland epithelium |
| Oocyte / Secondary oocyte | Present | — | Germline (p63 family role) |
| Leukocyte / Monocyte / T cell | Low | — | Immune lineage |
Key patterns:
- Dominant in basal epithelial stem cells and early differentiating layers across all stratified squamous epithelia
- Decreases during terminal differentiation (lower in mature keratinocytes, cornified layers)
- Strong in ductal/glandular structures (hair follicles, sebaceous glands, sweat glands, pancreatic ducts, breast ducts)
- Lower in simple columnar epithelia (lungs, gastrointestinal)
- Regulatory role in stemness: Enriched in stem/progenitor populations; decreases upon differentiation
Single-cell expression datasets
Notable datasets with TP63 expression:
GTEx snRNAseq atlas (E-ANND-2): 209,126 cells
- TP63 is a marker gene (score: 54.06) in epithelial clusters with ~1.84-fold enrichment
- Covers: breast, lung, skin, heart, esophagus, skeletal muscle, prostate
Smoking effects in airway epithelium (E-CURD-114): 81,801 cells
- Basal epithelial cells, immune cells, and smoking-responsive populations
Adult breast epithelium (E-ENAD-21, E-CURD-7): 867 cells
- Basal and luminal epithelial compartments
Lung IPF (E-GEOD-86618): 540 cells
- Control and disease samples; TP63 expression altered in fibrosis
Dental follicle organoids (E-MTAB-10596): 3,388 cells
- Epithelial stem cell-derived organoids
TP63 as a marker: TP63 specifically enriches basal epithelial stem cells across tissues, serving as a lineage-defining marker for the stratified epithelial progenitor compartment. Expression drops dramatically upon terminal differentiation.
Disease associations
Mendelian/Monogenic Diseases
| Disease | OMIM/Mondo/Orphanet ID | Inheritance | Evidence |
|---|---|---|---|
| Ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3 (EEC syndrome 3) | OMIM:604292 / MONDO:0011428 | Autosomal dominant | Definitive |
| Rapp-Hodgkin syndrome | OMIM:129400 / MONDO:0007508 | Autosomal dominant | Definitive |
| Limb-mammary syndrome | OMIM:603543 / MONDO:0011334 / ORPHANET:69085 | Autosomal dominant | Definitive |
| ADULT syndrome | OMIM:103285 / MONDO:0007072 / ORPHANET:978 | Autosomal dominant | Definitive |
| Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome | OMIM:106260 / ORPHANET:1071 / MONDO:0007124 | Autosomal dominant | Definitive |
| EEC syndrome | ORPHANET:1896 | Autosomal dominant | Supportive |
| Premature ovarian failure 21 | OMIM:620311 / MONDO:0957216 | Autosomal dominant | Strong |
| Split hand-foot malformation 4 | MONDO:0011535 / ORPHANET:2440 | Autosomal dominant | Moderate |
| TP63-related ectodermal dysplasia spectrum with limb and orofacial malformations | MONDO:1040001 | Autosomal dominant | Strong |
| Ankyloblepharon filiforme adnatum-cleft palate syndrome | ORPHANET:1072 | Autosomal dominant | Supportive |
Phenotype Associations (Top 30 HPO Terms)
| HPO ID | Phenotype |
|---|---|
| HP:0000006 | Autosomal dominant inheritance |
| HP:0000175 | Cleft palate |
| HP:0000202 | Orofacial cleft |
| HP:0000204 | Cleft upper lip |
| HP:0000968 | Ectodermal dysplasia |
| HP:0000271 | Abnormality of the face |
| HP:0001171 | Split hand |
| HP:0001839 | Split foot |
| HP:0001597 | Abnormal nail morphology |
| HP:0001596 | Alopecia |
| HP:0000365 | Hearing impairment |
| HP:0000405 | Conductive hearing impairment |
| HP:0002557 | Hypoplastic nipples |
| HP:0002836 | Bladder exstrophy |
| HP:0000668 | Hypodontia |
| HP:0000670 | Carious teeth |
| HP:0000677 | Oligodontia |
| HP:0000687 | Widely spaced teeth |
| HP:0000689 | Dental malocclusion |
| HP:0002208 | Coarse hair |
| HP:0002209 | Sparse scalp hair |
| HP:0002225 | Sparse pubic hair |
| HP:0002231 | Sparse body hair |
| HP:0000982 | Palmoplantar keratoderma |
| HP:0000958 | Dry skin |
| HP:0000962 | Hyperkeratosis |
| HP:0000966 | Hypohidrosis |
| HP:0000970 | Anhidrosis |
| HP:0000561 | Absent eyelashes |
| HP:0001159 | Syndactyly |
Complex-Disease/GWAS Associations (Top 30)
| Trait | Variant/Gene | Chr | P-value |
|---|---|---|---|
| Lung cancer | TP63 | 3 | 7.0e-26 |
| Non-small cell lung cancer | TPRG1-TP63 | 3 | 1.0e-20 |
| Lung adenocarcinoma | TP63 | 3 | 7.0e-17 |
| Cutaneous squamous cell carcinoma | TPRG1-TP63 | 3 | 6.0e-15 |
| EGFR mutation-positive lung adenocarcinoma | TP63 | 3 | 9.0e-13 |
| Lung adenocarcinoma | TP63 | 3 | 7.0e-12 |
| Lung adenocarcinoma | TP63 | 3 | 7.0e-12 |
| Squamous cell carcinoma | TPRG1-TP63 | 3 | 1.0e-11 |
| Bladder cancer | TP63-P3H2 | 3 | 2.0e-11 |
| Bladder cancer | TP63-P3H2 | 3 | 2.0e-10 |
| Lung cancer | TP63 | 3 | 7.0e-10 |
| Serum CC16 levels | TP63 | 3 | 5.0e-10 |
| Lung cancer | TP63 | 3 | 4.0e-09 |
| Acute lymphoblastic leukemia (childhood) | TP63 | 3 | 9.0e-09 |
| Acute lymphoblastic leukemia (childhood) | TP63 | 3 | 2.0e-08 |
| Pancreatic cancer | TP63 | 3 | 2.0e-08 |
| Acute lymphoblastic leukemia (childhood) | TP63 | 3 | 3.0e-08 |
| Psoriasis | TP63-P3H2 | 3 | 4.0e-08 |
| Chlamydia trachomatis PorB antibody levels | TPRG1-TP63 | 3 | 5.0e-08 |
| Pancreatic cancer | TP63 | 3 | 5.0e-08 |
| Urinary bladder cancer | TP63-P3H2 | 3 | 6.0e-08 |
| Postoperative stroke after cardiac surgery | TP63 | 3 | 4.0e-07 |
| Urinary bladder cancer | TP63-P3H2 | 3 | 1.0e-07 |
| Psoriasis | TP63-P3H2 | 3 | 8.0e-06 |
| Metabolite levels | P3H2 | 3 | 9.0e-06 |
| Lung cancer in never smokers | TP63 | 3 | 9.0e-07 |
| Lung cancer | TP63 | 3 | 1.0e-06 |
| Brain imaging | TPRG1-TP63 | 3 | 1.0e-06 |
| Systemic lupus erythematosus | TP63 | 3 | 2.0e-06 |
| Circulating leptin levels in high cardiovascular risk | TP63 | 3 | 3.0e-06 |